# C_2023039EN.01002301.xml

| 1.2.2023 | EN | Official Journal of the European Union | C 39/23 |
| --- | --- | --- | --- |

1.2.2023

EN

Official Journal of the European Union

C 39/23

---

Prior notification of a concentration

(Case M.10825 – DAVITA / MEDTRONIC / MEDTRONIC RENAL CARE SOLUTIONS)

Candidate case for simplified procedure

(Text with EEA relevance)

(2023/C 39/10)

1.

This notification concerns the following undertakings:

| — | DaVita Inc. (‘DaVita’, U.S.), |
| --- | --- |

—

DaVita Inc. (‘DaVita’, U.S.),

| — | Medtronic, Inc. (‘Medtronic’, U.S.), controlled by Medtronic plc., |
| --- | --- |

—

Medtronic, Inc. (‘Medtronic’, U.S.), controlled by Medtronic plc.,

| — | Medtronic’s Renal Care Solutions Business (‘RCS business’, U.S.), controlled by Medtronic. |
| --- | --- |

—

Medtronic’s Renal Care Solutions Business (‘RCS business’, U.S.), controlled by Medtronic.

DaVita and Medtronic will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the RCS business.

The concentration is accomplished by way of purchase of shares.

2.

| — | DaVita provides kidney dialysis services through a network of outpatient dialysis centres, |
| --- | --- |

—

DaVita provides kidney dialysis services through a network of outpatient dialysis centres,

| — | Medtronic is a global healthcare technology company dedicated to searching out and finding solutions to the most challenging human health problems, |
| --- | --- |

—

Medtronic is a global healthcare technology company dedicated to searching out and finding solutions to the most challenging human health problems,

| — | The RCS business is active in the research, development, manufacture, license, commercialisation and distribution and sale of renal care products and other medical devices used in the treatment of patients with end-stage renal disease (including dialysis machines, related items used in connection with dialysis treatments, catheters and other devices used in connection with the creation or maintenance of vascular access). |
| --- | --- |

—

The RCS business is active in the research, development, manufacture, license, commercialisation and distribution and sale of renal care products and other medical devices used in the treatment of patients with end-stage renal disease (including dialysis machines, related items used in connection with dialysis treatments, catheters and other devices used in connection with the creation or maintenance of vascular access).

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 5 days following the date of this publication. The following reference should always be specified:

M.10825 – DAVITA / MEDTRONIC / MEDTRONIC RENAL CARE SOLUTIONS

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---